Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996721 · ClinicalTrials.gov registry record · Phase 4
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
A Phase 4 study of Myocardial Infarction and Death, sponsored by Intermountain Health Care.
- Completed
- Registry status
- Phase 4
- Development phase
- 634
- Enrollment target
- 1
- Study location
NCT02996721 is a Phase 4 study of Myocardial Infarction and Death that has completed, run by Intermountain Health Care. The registered enrollment target is 634 participants, below the 4,672-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02996721, a Phase 4 study of Myocardial Infarction and Death, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 634 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates whether achieving 25-hydroxyvitamin D (25\[OH\] Vit D) levels (\>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events. Half of the patients will be randomized to receive standard of care and half will receive clinical management of 25\[OH\] Vit D levels.
Conditions Studied
Interventions
- BIOLOGICAL Vitamin D3
Study Locations (1)
Utah
- Intermountain Medical Center - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 634 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02996721
The ClinicalTrials.gov registry entry for NCT02996721 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 634 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,672-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (86% lower). The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which Vitamin D3 is the first listed.
NCT02996721 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT02996721 about?
NCT02996721 is a clinical study titled "A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients". This study evaluates whether achieving 25-hydroxyvitamin D (25\[OH\] Vit D) levels (\>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events. Half of the patients will be randomized to receive standard of care and half will receive clinical...
What is the current status of trial NCT02996721?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 634 participants. The study started on 2017-04-03. Estimated completion is 2025-09-04.
What conditions does trial NCT02996721 study?
This clinical trial studies the following conditions: Myocardial Infarction, Death, Cerebral Vascular Accident, Heart Failure Hospitalization.
What interventions are being tested in trial NCT02996721?
The interventions under investigation include: Vitamin D3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02996721?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02996721 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
COMPLETED · Phase 4
-
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
COMPLETED · Phase 4
-
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
COMPLETED · Phase 4
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.